Global Blood Therapeutics Inc. logo

GBT

Global Blood Therapeutics Inc.

$68.49

Earnings Summary

Revenue
$2.11Mn
Net Profits
$-95.98Mn
Net Profit Margins
-4552.89%

Highlights

Revenue:

Global Blood Therapeutics Inc.’s revenue jumped +Inf% since last year same period to $2.11Mn in the Q4 2019. On a quarterly growth basis, Global Blood Therapeutics Inc. has generated +Inf% jump in its revenue since last 3-months.

Net Profits:

Global Blood Therapeutics Inc.’s net profit fell -95.06% since last year same period to $-95.98Mn in the Q4 2019. On a quarterly growth basis, Global Blood Therapeutics Inc. has generated -48.69% fall in its net profits since last 3-months.

Net Profit Margins:

Global Blood Therapeutics Inc.’s net profit margin jumped NaN% since last year same period to -4552.89% in the Q4 2019. On a quarterly growth basis, Global Blood Therapeutics Inc. has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Global Blood Therapeutics Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-1.18
EPS Estimate Current Year
-1.18

Highlights

EPS Estimate Current Quarter:

Global Blood Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.18 - a 9.23% jump from last quarter’s estimates.

EPS Estimate Current Year:

Global Blood Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -1.18.

Key Ratios

Key ratios of the Global Blood Therapeutics Inc. post its Q1 2022 earnings

Earning Per Share (EPS)
-1.26
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-1.49

Highlights

Earning Per Share (EPS):

Global Blood Therapeutics Inc.’s earning per share (EPS) fell -4.13% since last year same period to -1.26 in the Q1 2022. This indicates that the Global Blood Therapeutics Inc. has generated -4.13% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Global Blood Therapeutics Inc.’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Global Blood Therapeutics Inc.’s return on equity (ROE) stands at -1.49.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-1.3
-1.26
3.08%

Company Information

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

Organisation
Global Blood Therapeutics Inc.
Industry
Health technology
CEO
Ted Love

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*